Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
Primary Objectives:
Secondary Objectives:
Full description
This study will seek to enroll every eligible patient enrolled in TBTC Study 23. Consenting patients will be asked to undergo measurements of isoniazid (if receiving), rifabutin and 25-OH desacetyl rifabutin levels at a time point in the study when steady state rifabutin levels are expected to have been achieved (at least two weeks following the start of rifabutin).
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion:
Exclusion:
Primary purpose
Allocation
Interventional model
Masking
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal